Existing drug Navitoclax shows potential in reducing senescent osteoclasts and providing relief for lower back pain, according to a study in mice. Senescent osteoclasts, responsible for breaking down deteriorated bone tissue, contribute to the development of lower back pain. Further clinical trials are needed to validate the effectiveness of Navitoclax in treating spine pain in humans.